PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...

Cabaletta Bio, Inc. ( (CABA)) has released its Q3 earnings. Here is a breakdown of the information Cabaletta Bio, Inc. presented to its investors. Cabaletta Bio, Inc. is a clinical-stage ...

Initial Phase 1 of 2 RESET-Myositis and RESET-SLE clinical trial data of the investigational therapy, CABA-201, revealed positive outcomes. The first two study participants did not exhibit infections ...

CABA-201, an investigational therapy by Cabaletta Bio, Inc. has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) as a possible treatment for lupus and lupus nephritis ...